For instance, the efficiency of Trastuzumab, which targets HER2 receptors in breast cancer, has been investigated using CoC to determine its targeting efficiency.[67] It was found that the SKBR3 cell line, which overexpresses HER2, had higher cell death rates as compared to the MCF‐7 cells, which lack HER2 receptors, indicating effective targeting. This evidence concerns the gene ERBB2 and breast cancer.